Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis - NCT04999020

Part A: Proportion Of Participants With A ≥ 20-point Improvement Response On International Myositis Assessment And Clinical Studies-Total Improvement Score (IMACS-TIS) (TIS20) At Week 26 Of The Randomized Controlled Period, Part B: Proportion Of Participants With A ≥ 20-point Improvement Response On TIS20 At Week 50, Part A: Mean TIS At Week 26, (and 27 more...)